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Caro Research Institute, Concord, MA, USA, 2 Caro Research Institute, Halifax, NS, Canada, 3 Caro Research Institute, Dorval, QC, Canada, 4 Sanofi-Aventis, Guildford, Surrey, UK, 5 Cardiff Research Consortium, Cardiff, UK OBJECTIVE: Often cost-effectiveness analyses must be undertaken before a price for the product has been set. This study evaluated the expected cost-effectiveness of rimonabant, the first selective CB-1 receptor blocker, for treatment of patients with dyslipidemia in the UK under various price assumptions. METHODS: A Markov model (SHAPE) was developed using data from clinical trials, published risk equations and UK patient profiles from the Health Outcomes Data Repository Database (HODaR) registry. Patients transition from At Risk or Diabetes to CVD based on UKPDS 68 or Framingham Heart study equations, or to death based on UK life-tables, and to diabetes (San Antonio Heart study) and subsequent CVD events (Saskatchewan equations). UK costs for acute resource use upon transition as well as longer term routine management are accrued in 2005 GBP. Age-dependent utilities are calculated and tariffs for all events and states are applied. Rimonabant effects on cardiometabolic risk factors were taken from the RIO Lipids trial. Ten year and lifetime horizons were examined; all outcomes were discounted at 3.5%/yr. Extensive probabilistic sensitivity analyses were carried out. RESULTS: Over ten years, >13% of patients are expected to suffer a cardiovascular event with a loss of more than 1045 QALYs and a cost above £600,000 per 1000 patients. Adding rimonabant to diet & exercise for only one year is estimated to gain >100 QALYs over a lifetime. Preliminary cost-effectiveness ratios remained acceptable (less then ≤20,000/QALY) under a wide range of assumptions and when testing hypothetical prices as high as ≤8 per day. CONCLU-SIONS: Based on the reductions in total to HDL cholesterol ratio, weight and other risk factors seen in RIO Lipids trial, rimonabant should substantially reduce cardiovascular risk in obese or overweight patients with dyslipidemia and result in an acceptable cost-effectiveness ratio.
METHODS & CONCEPTS I MC1 GROWTH, CHARACTERISTICS, AND QUALITY OF THE COST-UTILITY LITERATURE THROUGH 2003
Palmer JA 1 , Cohen JT 2 , Cochran GL 3 , Eldar-Lissai A 4 , Greenberg D 5 , Lavelle TA 6 , Wang ST 7 , Neumann PJ 2 1 Tufts-New England Medical Center, Boston, MA, USA, 2 Tufts University 1976-2001 and 2002-2003 data, most studies were based in the US (61%, 53%) and written by academics (90%, 92%). Studies examined treatment (63%, 62%) more than primary (14%, 16%) and secondary (22%, 21%) prevention. The most frequent condition studied was cardiovascular disease (21%, 18%). Percentage of funding by the pharmaceutical and device industry did not change substantially (19%, 23%). Studies improved with time across the two datasets: disclosing funding source (65% vs. 71%), stating year of currency (76% vs. 82%), reporting incremental ratios (59% vs. 79%), and using probabilistic sensitivity analyses (9% vs. 28%). CONCLUSIONS: The publication of CUAs has accelerated in recent years. Use of recommended methods has increased, although a sizeable number of analyses still do not adhere to best practice. Continued monitoring of these trends is crucial to enhancing the quality of the field. . The 15Ds was innovated by the literature and pragmatic experience with the 15D. RESULTS: The 15Ds contains 15 contemporary dimensions with five states (i.e. the conventional 15D), 15 recall/response dimensions with six states for transitions, and three validation dimensions. The recall/response dimensions adjust subjects' contemporary states for RB/RS. The validation dimensions contain a comparison of the subject's general health state to the health of a same-age population (5 states), RB/RS comparison for health transitions (6 states), and comparison for the level of healing (illness conceptualization, 5 states). A preliminary analysis revealed that patients have more sensitivity for changes measured as the recall/response items than for changes in the contemporary items over time. The 15Ds gives slightly better outcomes in the index changes and offers higher discrimination for the changes of HRQoL when compared with the conventional 15D. CONCLUSIONS: The 15Ds can produce 15-dimensional contemporary health profiles, 15-dimensional recall/response health profiles, overall HRQoL index for both 15Ds and 15D, and approximations for the validation of transitions, health and illness. The 15Ds is recommended for recall (e.g. acute conditions when no baseline HRQoL is obtainable) and RB/RS adjustment.
MC3 USING SIMULATIONS TO EXPLORE THE INFLUENCE OF COMPETING RISK ON TREATMENT-EFFECT
Kent DM 1 , Hayward RA 2 1 Tufts-New England Medical Center, Boston, MA, USA, 2 University of Michigan, Ann Arbor, MI, USA OBJECTIVES: In previous work, we explored through computer-aided simulated clinical trials how heterogeneity of baseline risk can lead to heterogeneity of treatment-effect under a variety of assumptions. We now explore how heterogeneity of competing risks affect treatment-effect heterogeneity under a variety of assumptions. METHODS: Using simulated clinical trials in which the intervention has a constant effect on diseasespecific risk (odds ratio = 0.7) but no effect on competing risk and in which outcomes in individuals are determined by varying 2 parameters: (1) the overall risk of the outcome of interest and (2) the ratio between the competing risk and the disease-specific (i.e. treatment-responsive) risk. RESULTS: Under conditions in the simulations, the odds ratio of the treatment-effect on the overall outcome is highly dependent on the ratio of the competing and disease-specific risk, decreasing as this ratio increases. Although the absolute treatment-effect increases with increasing overall risk, the odds ratio for the treatment decreases as the overall risk increases (holding constant the ratio between diseasespecific and competing risk). When disease-specific outcomes are measured, a similar relationship between treatment-effect and overall risk is observed, although the decrease in the odds ratio with increasing risk is greatly attenuated. Detecting significant treatment-effect heterogeneity (on the odds ratio scale) based on competing risk is likely to occur only when competing risk is very high or when patients can be sub-grouped by variables which distinguish between disease-specific and competing risk. CONCLUSION: The ratio of competing risk to disease-specific risk in a population can have an important impact on the measured treatment effect, even when disease-specific outcomes are measured. Detection of competing-risk-based treatment-effect heterogeneity may depend on the identification of risk factors that differentiate disease-specific from competing risk. Simulations can be useful to anticipate the magnitude of these effects when planning a clinical trial.
MC4 BREAKING THE SILENCE: THE EFFECTS OF EXPLICIT INSTRUCTIONS ON INCORPORATING INCOME IN TTO EXCERCISES
Krol M 1 , Brouwer W 1 , Sendi P 2 1 The institute for Medical Technology Assessment, Rotterdam, The Netherlands, 2 Institute for Clinical Epidemiology, Basel, Switzerland OBJECTIVES: The recommendation of the US Panel to incorporate productivity costs in terms of health effects (QALYs) in a cost-effectiveness analysis aroused quite some debate. A crucial yet under-explored question in this debate is whether people include effects of ill-health on income in health state valuations (HSV). The same holds for the actual inclusion in HSV of the effects of ill-health on leisure. This study aims to test whether respondents to health-state valuations using TTO questions include the effects of ill-health on income and leisure when the measure is silent on both. Moreover, it tests the consequences of explicit instructions to either include or exclude the incomeeffects in HSV. METHODS: Three questionnaires were developed and administered among the general public. Respondents were asked to value three distinct EQ-5D health-states using TTO. In version 1 respondents did not receive instructions on including or excluding income-effects in their valuations, but inclusion was assessed afterwards. In versions 2 and 3 respondents were instructed upfront to incorporate income-effects or to assume that income would not change. They were furthermore asked whether they included the effects of ill-health on leisure-time in their HSV. RESULTS: In version 1 64% of the respondents spontaneously included income-effects in their HSV. In version 2 and 3 88% included leisure-time. There were no differences in the valuations of respondents including or excluding income-effects, also in case of explicit instruction. Inclusion of leisure-time resulted in a significantly lower TTO-value in only one of the three health-states. CONCLUSIONS: Respondents do not consistently include income-and leisure-effects in their valuations. Including income-effects (spontaneously or instructed) does not seem to affect TTO-valuations and may therefore best be placed on the cost-side of the cost-effectiveness ratio. Leisure-
